The bounce off the 50-day average holds, but weekly momentum cools
Novo Nordisk gains 0.4% as buyers retake volume control after earnings
The bounce off the 50-day average holds, but weekly momentum cools
Our view last week
Among pharma stocks, Novo Nordisk stock closed the week down 3.5%, with sellers firmly in control: 89% of volume turned to selling and buyer dominance suddenly collapsed. Money flow still stays positive, though cooling, while the weekly RSI slides toward neutral territory. After last week's slowdown, technical analysis shows further fading momentum, with the August 5 earnings report now close at hand.
This week's summary
With earnings out of the way, Novo Nordisk catches its breath: the week closes slightly higher and buyers reclaim control of volume, 65% versus last week's 89% in selling. On the daily chart the rebound comes right off the 50-day moving average, a 6% recovery from the lows. The picture is still less bright than a month ago though: weekly cash flow and momentum have cooled, and the weekly RSI has drifted back to neutral territory.
IQS Phase
49
ordinary
Signal Strength
70
high · wide & volatile
Sizing
FULL
Ranking
#25 / 132
US stocks in progress
Trade P&L %
+7.70%
from signal to date, no stop loss
Rank position
ranks 25th among the 132 Longs already running for US stocks in our ranking, with a signal strength of 70 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein strong phase
Performanceweekly +1.93% · monthly +2.08%
NVO belongs to the health care sector (reference ETF XLV). The sector is classified in strong phase according to our weekly reading.
restricted Platinum content